1313738-80-5

Basic information

• Product Name: 1-benzyl-1,2,5,6-tetrahydropyridin-3-ylboronic acid pinacol ester
• Synonyms: 1-benzyl-1,2,5,6-tetrahydropyridin-3-ylboronic acid pinacol ester;1-benzyl-5-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,6-tetrahydropyridine;1-Benzyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl);1-benzyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine
• CAS NO: 1313738-80-5
• Molecular Formula: C₁₈H₂₆BNO₂
• Molecular Weight: 317.23082
• Mol File: 1313738-80-5.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 357.7±52.0 °C(Predicted)
• Appearance: /
• Density: 1.05±0.1 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• PKA: 8.34±0.40(Predicted)
• CAS DataBase Reference: 1-benzyl-1,2,5,6-tetrahydropyridin-3-ylboronic acid pinacol ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-benzyl-1,2,5,6-tetrahydropyridin-3-ylboronic acid pinacol ester(1313738-80-5)
• EPA Substance Registry System: 1-benzyl-1,2,5,6-tetrahydropyridin-3-ylboronic acid pinacol ester(1313738-80-5)

Safety Data

• Hazardous Substances Data: 1313738-80-5(Hazardous Substances Data)

Usage

General Description

1-Benzyl-1,2,5,6-tetrahydropyridin-3-ylboronic acid pinacol ester is a chemical compound with a boronic acid functional group and a tetrahydropyridine ring structure. It is commonly used in organic synthesis and medicinal chemistry as a building block for the preparation of various pharmaceutical compounds. This chemical has been studied for its potential applications in drug discovery and development. It is typically used as a reagent in Suzuki-Miyaura coupling reactions to form carbon-carbon bonds and in other cross-coupling reactions. 1-Benzyl-1,2,5,6-tetrahydropyridin-3-ylboronic acid pinacol ester has also been investigated for its potential use as a ligand in catalytic processes. Overall, this compound is important in the field of organic chemistry and drug development due to its versatile reactivity and potential biological activity.

Upstream product

• 100-44-7 benzyl chloride 
• 329214-79-1 3-(4,4,5,5,-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine 
• 50606-58-1 N-benzyl-3-piperidinone hydrochloride 
• 40114-49-6 1-benzyl-3-piperidone 

Downstream Products

• 676495-45-7 6-[4-(1-benzyl-1,2,5,6-tetrahydro-pyridin-3-yl)-phenoxy]-nicotinamide hydrochloride salt 

Relevant articles and documents

Preparation method of N-substituted-tetrahydropyridine-3/4-boric acid/ester

The invention discloses a preparation method of N-substituted tetrahydropyridine-3/4-boric acid/ester, and belongs to the technical field of organic boric acid chemistry. The method comprises the following steps: carrying out a reaction on pyridine-3/4-boric acid/ester and a halide to form a quaternary salt, and reducing the quaternary salt with sodium/potassium borohydride in an aprotic solvent to generate N-substituted-tetrahydropyridine-3/4-boric acid/ester. According to the method, easily-synthesized pyridine-3/4-boric acid/ester is used as a raw material, the product can be obtained through two continuous steps, and the reaction selectivity is high, so that the defect that palladium-catalyzed coupling or ultralow temperature is needed when substituted piperidone is adopted as a raw material is overcome, the method is verified on the hectogram scale, and a concise and efficient synthesis path is provided for preparation of the compound.

SUBSTITUTED FUSED TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF

The present invention relates to substituted fused tricyclic compounds of formula (I) or (Ia), their tautomers, polymorphs, stereoisomers, prodrugs, solvates, co-crystals, pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by JAK activity. The compounds of the present invention are useful in the treatment, prevention or suppression of diseases and disorders mediated by JAK activity. Such conditions include, but not limited to, arthritis, Alzheimer's disease, autoimmune thyroid disorders, cancer, diabetes, leukemia, T-cell prolymphocytic leukemia, lymphoma, myleoproliferation disorders, lupus, multiple myeloma, multiple sclerosis, osteoarthritis, sepsis, psoriatic arthritis, prostate cancer, T-cell autoimmune disease, inflammatory diseases, chronic and acute allograft transplant rejection, bone marrow transplant, stroke, asthma, chronic obstructive pulmonary disease, allergy, bronchitis, viral diseases, or Type I diabetes, complications from diabetes, rheumatoid arthritis, asthma, Crohn's disease, dry eye, uveitis, inflammatory bowel disease, organ transplant rejection, psoriasis and ulcerative colitis. The present disclosure also relates to process for the preparation of such compounds, and to pharmaceutical compositions containing them.